IP Library Granted Patent US 8,143,210
Granted Patent B2
US 8,143,210 · App. 11/775,824 · Granted Mar 27, 2012

Enzyme treatment of foodstuffs for celiac sprue

Assignees: The Board of Trustees of the Leland Stanford Junior University; Alvine Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,143,210
App. No.
11/775,824
Granted
Mar 27, 2012
Kind
B2
Abstract

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Claims (7)

1. A composition, comprising:

isolated Myxococcus xanthus prolyl endopeptidase (PEP) consisting of the amino acid sequence forth in SEQ ID NO:47, admixed with gluten-containing food.

2. The composition of claim 1 , wherein said isolated Myxococcus xanthus prolyl endopeptidase (PEP) comprising the amino acid sequence forth in SEQ ID NO:47 is provided in a unit dosage form containing an amount of the isolated Myxococcus xanthus PEP effective to cleave a gluten oligopeptide having the amino acid sequence of SEQ ID NO:12 to fragments shorter than 8 amino acids and a pharmaceutically acceptable excipient.

3. The composition of claim 2 , wherein the isolated Myxococcus xanthus PEP is a recombinant protein.

4. The composition of claim 2 , wherein the unit dosage form of isolated Myxococcus xanthus PEP is coated with an enteric coating.

5. The composition of claim 2 , wherein the amount of isolated Myxococcus xanthus PEP in the unit dosage form is 500 units to 20,000 units, wherein one unit is the amount of enzyme required to hydrolyze 1 μmol Cbz-Gly-Pro-pNA per min under specified conditions.

6. The composition of claim 2 , wherein the amount of isolated Myxococcus xanthus PEP in the unit dosage is from 0.1 mg to 500 mg.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2012
From: ALVINE PHARMACEUTICALS, INC.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 029504/0018 →
CONFIRMATORY LICENSE Recorded Mar 28, 2012
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027943/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2009
From: CELIAC SPRUE RESEARCH FOUNDATION
To: ALVINE PHARMACEUTICALS, INC.
Reel/Frame 022327/0463 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2008
From: LU, SHAN; BETHUNE, MICHAEL; KHOSLA, CHAITAN
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 020374/0565 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2008
From: INDU, ISAACS; STROHMEIER, GREGG; GASS, JONATHAN; PYLE, GAIL G.; GRAY, GARY M.
To: CELIAC SPRUE RESEARCH FOUNDATION
Reel/Frame 020374/0575 →
Continuity (10)
Continuation In Part 10969314 · Oct 19, 2004
Continuation In Part 10367405 · Feb 14, 2003
Provisional Application 60565668 · Apr 26, 2004
Provisional Application 60357238 · Feb 14, 2002
Provisional Application 60380761 · May 14, 2002
Provisional Application 60392782 · Jun 28, 2002
Provisional Application 60422933 · Oct 31, 2002
Provisional Application 60428033 · Nov 20, 2002
Provisional Application 60435881 · Dec 20, 2002
Related Publication 20080095710A1 · Apr 24, 2008